A Multi-center, Single-dose, Open-label, Parallel Design, Pharmacokinetics Study of HRS9531injection in Healthy Subjects and Subjects With Impaired Renal Function.

This document provides information about a clinical trial, NCT06246175, conducted by Fujian Shengdi Pharmaceutical Co., Ltd. The trial aims to assess the pharmacokinetics of a drug called HRS9531 in participants with impaired kidney function compared to healthy participants. It is a single-dose, open-label, parallel design trial in Phase 1. The intervention involves receiving a single dose of HRS9531 injection. The trial is not yet recruiting and aims to enroll 32 participants, with an estimated completion date of July 31, 2024. The eligibility criteria include factors such as age, body mass index, renal function, and medical history. The study is open to all genders, and healthy volunteers are also accepted. The document provides administrative information such as the NCT number and contact details for the primary and backup contacts. [Extracted from the article]